| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 0.89 [0.82, 0.95] | | < 1 | | 25% | 58 studies (58/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| death or transfer to ICU | 0.79 [0.50, 1.24] | | < 1 | | 0% | 2 studies (2/-) | 84.9 % | some concern | not evaluable | moderate | crucial | - |
| deaths | 0.90 [0.86, 0.94] | | < 1 | | 19% | 96 studies (96/-) | 100.0 % | some concern | critical | moderate | crucial | 1 |
| deaths (time to event analysis only) | 0.81 [0.68, 0.97] | | < 1 | | 38% | 13 studies (13/-) | 99.0 % | some concern | low | moderate | crucial | - |
| clinical deterioration | 0.71 [0.58, 0.86] | | < 1 | | 49% | 21 studies (21/-) | 100.0 % | some concern | low | moderate | important | - |
| clinical improvement | 1.16 [1.04, 1.29] | | > 1 | | 40% | 25 studies (25/-) | 99.7 % | some concern | critical | moderate | important | - |
| clinical improvement (14-day) | 1.32 [0.95, 1.83] | | > 1 | | 50% | 7 studies (7/-) | 94.9 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (28-day) | 1.51 [1.04, 2.17] | | > 1 | | 51% | 9 studies (9/-) | 98.5 % | some concern | serious | moderate | important | - |
| clinical improvement (7-day) | 1.54 [0.73, 3.22] | | > 1 | | 70% | 4 studies (4/-) | 87.3 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.11 [1.01, 1.22] | | > 1 | | 20% | 13 studies (13/-) | 98.9 % | some concern | critical | moderate | important | - |
| death or ventilation | 0.90 [0.84, 0.96] | | < 1 | | 58% | 23 studies (23/-) | 100.0 % | some concern | critical | moderate | important | - |
| hospital discharge | 1.07 [1.00, 1.15] | | > 1 | | 63% | 12 studies (12/-) | 97.1 % | some concern | critical | moderate | important | - |
| hospitalization | 1.00 [0.14, 7.34] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | some concern | not evaluable | moderate | important | - |
| mechanical ventilation | 0.89 [0.81, 0.99] | | < 1 | | 16% | 27 studies (27/-) | 98.6 % | some concern | critical | moderate | important | 1 |
| radiologic improvement (14-day) | 3.02 [1.77, 5.14] | | > 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| viral clearance | 2.88 [1.09, 7.63] | | > 1 | | 90% | 5 studies (5/-) | 98.3 % | some concern | not evaluable | moderate | important | - |
| viral clearance (time to event analysis only) | 1.18 [0.54, 2.54] | | > 1 | | 83% | 2 studies (2/-) | 66.0 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 1.01 [0.04, 28.87] | | > 1 | | 98% | 4 studies (4/-) | |